Protein genomics reveals markers of chemotherapy resistance and prognosis in triple-negative breast cancer

Researchers at Baylor College of Medicine, the Broad Institute of the Massachusetts Institute of Technology (MIT) and Harvard, as well as Washington University in St.

"TNBC is one of the most difficult types of breast cancer to treat, and standard treatments require multiple chemotherapy drugs and unfortunately often fail to cure patients," said

The research team used an innovative analytical method, and they previously developed a method called microscale protein genomics to analyze tumor biopsies

"Proteomic analysis of pretreated biopsies uniquely reveals metabolic pathways associated with treating drug resistance, including fatty acid metabolism," Anurag said

The team then analyzed

"In other cancer types, the loss of LIG1 has also been associated with a poor prognosis, suggesting that this deletion has broader clinical implications," Anurag said

This groundbreaking study clearly reveals the power of combining microscopic protein genome analysis with careful clinical research to generate new insights

The protein product of LIG1 is an important part

"This is an exciting result that demonstrates a very close collaboration between patients, oncology care teams and lab scientists," said